FDA Finalizes Policies Around Gene Therapies

February 3, 2020

Forecasting a boom in the gene therapy landscape, the Food and Drug Administration (FDA) last week finalized a number of policies for the development and assessment of gene therapies, BioPharma Dive reports.

According to the report, the FDA expects it could have 10-20 gene therapies in the pipeline each year by 2025.

“These therapies, once only conceptual, are rapidly becoming a therapeutic reality,” FDA Commissioner Stephen Hahn said in a statement.

To read the full report on BioPharma Dive, click here.

Share This Story!